Has William Litchfield, MD received payments from drug or device companies?

Yes. Drug and device makers reported $358,996 in general payments to William Litchfield, MD across 1,324 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean William Litchfield, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about William Litchfield, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

William Litchfield, MD

Endocrinology, Diabetes & Metabolism · Henderson, NVNPI 1629078100

Payments from drug & device makers

$358,996in general payments, 2019–2025

Across 1,324 payments — averaging $271.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$106K
Abbott$94K
Novo Nordisk AS$50K
Lilly USA, LLC$42K
Tandem Diabetes Care, Inc.$11K
Sanofi US Services Inc.$11K
plus $44K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	200	$106,289
Abbott	137	$94,246
Novo Nordisk AS	18	$50,347
Lilly USA, LLC	121	$41,529
Tandem Diabetes Care, Inc.	28	$11,241
Sanofi US Services Inc.	1	$10,980
Kowa Research Institute, Inc.	3	$10,165
Johnson & Johnson	13	$9,727
Esperion Therapeutics, Inc.	15	$3,485
AbbVie	32	$2,390
Insulet Corporation	28	$2,354
Amgen(2 entities)	68	$1,922
AstraZeneca(2 entities)	61	$1,427
Xeris Pharmaceuticals, Inc.	44	$830
Dexcom, Inc.	48	$792
Bayer	41	$768
Corcept Therapeutics	26	$762
Sanofi-aventis U.S. LLC	35	$745
Boehringer Ingelheim	43	$646
Radius Health, Inc.	30	$596
Recordati_rare_diseases_inc.	27	$593
Medtronic(2 entities)	18	$566
BETA Bionics, Inc.	16	$495
Mannkind Corporation	27	$482
IBSA Pharma Inc.	21	$417
Pfizer	16	$321
Amryt Pharma Holdings Ltd	9	$319
Kyowa Kirin, Inc.	9	$314
Novartis	14	$311
Senseonics, Incorporated	3	$293
Amneal Pharmaceuticals LLC	17	$271
Astellas Pharma US Inc	10	$265
Amarin Pharma, Inc.	14	$260
Lifescan, Inc.	10	$229
Nevro Corp.	1	$189
Ultragenyx Pharmaceutical Inc.	5	$180
Ascendis Pharma Endocrinology Inc	10	$168
Intra-sana Laboratories	21	$148
Shire North American Group Inc	2	$144
Almatica Pharma LLC	6	$138
Averitas Pharma Inc.	2	$138
Antares Pharma, Inc.	8	$132
Gilead	1	$124
Embecta Corp.	6	$122
Merck	7	$111
BD	5	$97
Biomarin Pharmaceutical Inc.	5	$89
Tolmar, Inc.	4	$88
Neurocrine Biosciences, Inc.	3	$83
Amphastar Pharmaceuticals, Inc.	4	$77
Chiesi USA, Inc.	3	$66
Kowa Pharmaceuticals America, Inc.	3	$63
Companion Medical, Inc.	3	$49
Madrigal Pharmaceuticals	2	$43
Ascensia Diabetes Care US Inc.	2	$40
Takeda Pharmaceuticals U.S.A., Inc.	2	$36
Acella Pharmaceuticals, LLC	2	$33
Strongbridge US Inc.	2	$29
Sequel Med Tech, LLC	1	$28
Soleno Therapeutics, Inc.	1	$28

How this compares

$358,996 in reported general payments places this provider in the 90th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

See all endocrinology, diabetes & metabolism providers in Nevada →

Medicare billing

Part B allowed, 2024

$502,217

Medicare patients

959

Services billed

17,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Henderson

Quang NguyenHenderson$2.9M
Carlos Hernandez-CassisHenderson$49K
Claudia VogelHenderson$12K
Omer TararHenderson$5K
Amira IbrahimHenderson$2K
Sehrish WaheedHenderson$835
Samer NakhleLas Vegas$14.5M
Betsy PalalLas Vegas$6.8M
Lisa AbbottReno$1.2M
Nitesh KuhadiyaReno$645K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →